BROOMFIELD, Colo., Aug. 1 ARCA biopharma, Inc., abiopharmaceutical company developing genetically-targeted therapies for heartfailure and other cardiovascular diseases, announced today that it hasappointed James Carr, PharmD, as vice president of marketing. In this newlycreated position, Mr. Carr will define and execute marketing programs tosupport the company's lead product candidate, Gencaro(TM) (bucindololhydrochloride), a pharmacologically unique beta-blocker and mild vasodilatorin late-stage development for heart failure.
"Jim brings senior pharmaceutical industry experience and a deep knowledgeof the heart failure market, which will be of significant value to ARCA as thecompany prepares to commercialize the first personalized cardiovascularmedicine," said Richard B. Brewer, president and chief executive officer ofARCA. "We are pleased to be able to attract talented professionals to help usaccelerate the company's growth and success, and welcome Jim to the ARCAteam."
Mr. Carr joins ARCA from Anesiva, Inc., where he served as vice presidentof marketing for pain management products since 2004. In this role, he wasresponsible for leading the development and launch teams for Zingo(TM), arapid acting topical anesthetic. Prior to Anesiva, Mr. Carr was withGlaxoSmithKline (GSK) for eight years, where he led the launch for thepost-myocardial infarction indication for Coreg(R) (carvedilol), a leadingtreatment for heart failure. During his tenure at GSK, Carr held managementpositions in professional relations, managed care marketing, medicaleducation, advisory boards, publications, and lifecycle management.
Prior to joining the pharmaceutical industry, Mr. Carr was a researcher atthe University at Buffalo School of Pharmacy. He earned a Doctor of Pharmacydegree from the University of Minnesota and conducted post-graduate work inthe area of polymorphic drug metabolism of beta-blockers, also at theUniversity of Minnesota.
About ARCA biopharma
ARCA biopharma, Inc. is a privately held company focused on developing andcommercializing genetically targeted therapies for heart failure and othercardiovascular diseases. The Company's lead product, Gencaro(TM) (bucindololhydrochloride), is a pharmacologically unique beta-blocker and mildvasodilator being developed for heart failure and other indications. ARCA hasidentified common genetic variations that predict individual patient responseto Gencaro. The company plans to file a New Drug Application with the U.S.Food and Drug Administration during the summer of 2008 for approval of Gencarofor the treatment of heart failure. The companion genetic test for Gencaro isin development by ARCA's partner, Laboratory Corporation of America. Ifapproved, Gencaro could become the first genetically personalizedcardiovascular therapy. For more information please visithttp://www.arcabiopharma.com.
SOURCE ARCA biopharma, Inc.